FiscalNote Holdings, Inc. (NOTE) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -20%. A quarter ago, it was expected that this company would post a loss of $0.10 per share when it actually produced a loss of $0.10, delivering no surprise.Over the last four quarters, the company has surpassed ...

Integral Ad Science (IAS) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 66.67%. A quarter ago, it was expected that this digital advertising verification company would post earnings of $0.12 per share when it actually produced earnings of $0.09, delivering a surprise of -25%.Over the la ...

Core Insights - Natural Gas Services (NGS) reported quarterly earnings of $0.38 per share, exceeding the Zacks Consensus Estimate of $0.27 per share, but down from $0.41 per share a year ago [1] - The company achieved a 40.74% earnings surprise and has surpassed consensus EPS estimates in all four of the last quarters [2] - NGS posted revenues of $41.38 million for the quarter, surpassing the Zacks Consensus Estimate by 1.53% and up from $36.91 million year-over-year [3] Financial Performance - The earnings surprise of 40.74% indicates strong performance relative to expectations [2] - Revenue growth of 12.6% year-over-year from $36.91 million to $41.38 million demonstrates positive sales momentum [3] - The company has consistently exceeded revenue estimates, achieving this in three of the last four quarters [3] Market Position and Outlook - NGS shares have declined approximately 23.7% year-to-date, contrasting with the S&P 500's decline of 3.8% [4] - The current Zacks Rank for NGS is 4 (Sell), indicating expectations of underperformance in the near future [7] - The consensus EPS estimate for the upcoming quarter is $0.28, with projected revenues of $41.51 million, and for the current fiscal year, the EPS estimate is $1.18 on revenues of $171.3 million [8] Industry Context - The Oil and Gas - Mechanical and Equipment industry, to which NGS belongs, is currently ranked in the bottom 8% of over 250 Zacks industries, suggesting a challenging environment [9] - The performance of NGS may be influenced by broader industry trends, as top-ranked industries tend to outperform lower-ranked ones significantly [9]

Financial Performance - Bolt Biotherapeutics reported a quarterly loss of $0.29 per share, better than the Zacks Consensus Estimate of a loss of $0.34, and compared to a loss of $0.28 per share a year ago, indicating an earnings surprise of 14.71% [1] - The company posted revenues of $1.22 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 19.45%, but down from $5.27 million in the same quarter last year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates just once and topped consensus revenue estimates three times [2] Stock Performance - Since the beginning of the year, Bolt Biotherapeutics shares have declined by approximately 33.1%, while the S&P 500 has decreased by 3.8% [3] - The current Zacks Rank for Bolt Biotherapeutics is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.34 on revenues of $0.99 million, and for the current fiscal year, it is -$1.27 on revenues of $3.79 million [7] - The estimate revisions trend for Bolt Biotherapeutics is mixed, and future stock movements will depend on management's commentary during the earnings call [3][4] Industry Context - The Medical - Biomedical and Genetics industry, to which Bolt Biotherapeutics belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Getty Images Holdings, Inc. reported a quarterly loss of $0.14 per share, significantly missing the Zacks Consensus Estimate of $0.03, marking an earnings surprise of -566.67% [1] - The company generated revenues of $224.08 million for the quarter ended March 2025, which was 4.71% below the Zacks Consensus Estimate, but slightly above the year-ago revenues of $222.28 million [2] - The stock has underperformed the market, losing about 13% since the beginning of the year compared to the S&P 500's decline of -3.8% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.03 on revenues of $236.26 million, and for the current fiscal year, it is $0.10 on revenues of $948.07 million [7] - The estimate revisions trend for Getty Images is currently unfavorable, resulting in a Zacks Rank 5 (Strong Sell), indicating expected underperformance in the near future [6] Industry Context - The Internet - Software industry, to which Getty Images belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a relatively strong industry performance [8] - Another company in the same industry, Domo, is expected to report a quarterly loss of $0.20 per share, with revenues projected to decline by 2.8% year-over-year [9]

Core Viewpoint - Karyopharm Therapeutics reported a quarterly loss of $2.77 per share, significantly better than the Zacks Consensus Estimate of a loss of $4.21, marking an earnings surprise of 34.20% [1] Financial Performance - The company posted revenues of $30.02 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 16.18%, compared to $33.13 million in the same quarter last year [2] - Over the last four quarters, Karyopharm has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - Karyopharm shares have declined approximately 40.7% since the beginning of the year, while the S&P 500 has decreased by 3.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$3.90 on revenues of $39.29 million, and for the current fiscal year, it is -$14.05 on revenues of $150.29 million [7] Industry Outlook - The Medical - Drugs industry, to which Karyopharm belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -12.90%. A quarter ago, it was expected that this drug developer would post a loss of $0.23 per share when it actually produced a loss of $0.28, delivering a surprise of -21.74%.Over the last four quarters, the company ...

Core Insights - iHeartMedia reported a quarterly loss of $0.63 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.47, and a significant decline from a loss of $0.12 per share a year ago, indicating a surprise of -34.04% [1] - The company generated revenues of $807.1 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 2.19% and showing a slight increase from $799.04 million in the same quarter last year [2] - iHeartMedia's stock has declined approximately 36.4% year-to-date, contrasting with the S&P 500's decline of -3.8% [3] Earnings Outlook - The earnings outlook for iHeartMedia is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.16 on revenues of $907.39 million, and for the current fiscal year at -$0.31 on revenues of $3.71 billion [7] - The company's Zacks Rank is currently 3 (Hold), suggesting that shares are expected to perform in line with the market in the near future [6] Industry Context - The Broadcast Radio and Television industry, to which iHeartMedia belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Topgolf Callaway Brands (MODG) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 375%. A quarter ago, it was expected that this maker of golf equipment and accessories would post a loss of $0.40 per share when it actually produced a loss of $0.33, delivering a surprise of 17.5 ...

Company Performance - Aquestive Therapeutics reported a quarterly loss of $0.24 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.17, representing an earnings surprise of -41.18% [1] - The company posted revenues of $8.72 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 28.14%, and down from $12.05 million in the same quarter last year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Stock Performance - Shares of Aquestive Therapeutics have declined approximately 21.6% since the beginning of the year, compared to a decline of -3.8% for the S&P 500 [3] - The current Zacks Rank for the stock is 4 (Sell), indicating expectations of underperformance in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.17 on revenues of $11.87 million, and for the current fiscal year, it is -$0.65 on revenues of $49.55 million [7] - The estimate revisions trend for Aquestive Therapeutics is currently unfavorable, which may change following the recent earnings report [6] Industry Context - The Medical - Drugs industry, to which Aquestive Therapeutics belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a relatively strong industry performance [8]